JP2015509714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509714A5 JP2015509714A5 JP2014558206A JP2014558206A JP2015509714A5 JP 2015509714 A5 JP2015509714 A5 JP 2015509714A5 JP 2014558206 A JP2014558206 A JP 2014558206A JP 2014558206 A JP2014558206 A JP 2014558206A JP 2015509714 A5 JP2015509714 A5 JP 2015509714A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- chimeric fusion
- fusion polypeptide
- mediated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 229920001184 polypeptide Polymers 0.000 claims description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 92
- 230000004927 fusion Effects 0.000 claims description 61
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 38
- 241000282465 Canis Species 0.000 claims description 32
- 230000001404 mediated effect Effects 0.000 claims description 32
- 208000024891 symptom Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 206010003246 arthritis Diseases 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 16
- 206010036030 Polyarthritis Diseases 0.000 claims description 16
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 14
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 8
- 230000000172 allergic effect Effects 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 8
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 8
- 230000000626 neurodegenerative effect Effects 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 206010037844 rash Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 208000010201 Exanthema Diseases 0.000 claims description 6
- 201000005884 exanthem Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229940122467 Nerve growth factor antagonist Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- -1 opioid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601712P | 2012-02-22 | 2012-02-22 | |
| US61/601,712 | 2012-02-22 | ||
| PCT/GB2013/050433 WO2013124666A1 (en) | 2012-02-22 | 2013-02-22 | Tumour necrosis factor receptor fusion proteins and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509714A JP2015509714A (ja) | 2015-04-02 |
| JP2015509714A5 true JP2015509714A5 (enExample) | 2016-04-14 |
Family
ID=47754861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558206A Pending JP2015509714A (ja) | 2012-02-22 | 2013-02-22 | 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9731007B2 (enExample) |
| EP (1) | EP2817326A1 (enExample) |
| JP (1) | JP2015509714A (enExample) |
| KR (1) | KR20140135766A (enExample) |
| CN (1) | CN104159916A (enExample) |
| AU (1) | AU2013223801B2 (enExample) |
| CA (1) | CA2865288A1 (enExample) |
| HK (1) | HK1201541A1 (enExample) |
| NZ (1) | NZ629309A (enExample) |
| SG (1) | SG11201405013RA (enExample) |
| WO (1) | WO2013124666A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2932515C (en) * | 2013-12-20 | 2023-08-01 | Intervet International B.V. | Caninized antibodies |
| CA2975017A1 (en) * | 2015-01-29 | 2016-08-04 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| WO2016149139A1 (en) * | 2015-03-13 | 2016-09-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
| CN104840945B (zh) * | 2015-03-25 | 2018-09-07 | 上海市松江区中心医院 | 诱骗受体3在治疗脓毒症药物中的应用 |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| JP7008020B2 (ja) | 2015-12-18 | 2022-01-25 | インターベット インターナショナル ベー． フェー． | ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体 |
| WO2017123642A1 (en) * | 2016-01-12 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis |
| CN119390821A (zh) * | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| JP2020080784A (ja) * | 2018-11-29 | 2020-06-04 | シスメックス株式会社 | 融合ポリペプチド、融合ポリペプチドの製造方法、及び融合ポリペプチドをコードするｄｎａ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| US8337842B2 (en) * | 2008-09-04 | 2012-12-25 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| CN101747440B (zh) * | 2008-12-18 | 2014-05-07 | 嘉和生物药业有限公司 | 一种TNFR-Fc融合蛋白及其用途 |
| CN101760506A (zh) * | 2008-12-25 | 2010-06-30 | 欣润(上海)生物药业有限公司 | 一种rhTNFR-Fc融合蛋白生物学活性的检测方法 |
| US8181211B2 (en) | 2009-03-30 | 2012-05-15 | John Mezzalingua Associates, Inc. | Total bandwidth conditioning device |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| CA2763439A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
-
2013
- 2013-02-22 CN CN201380010734.1A patent/CN104159916A/zh active Pending
- 2013-02-22 KR KR1020147026150A patent/KR20140135766A/ko not_active Withdrawn
- 2013-02-22 SG SG11201405013RA patent/SG11201405013RA/en unknown
- 2013-02-22 AU AU2013223801A patent/AU2013223801B2/en active Active
- 2013-02-22 US US14/380,277 patent/US9731007B2/en active Active
- 2013-02-22 CA CA2865288A patent/CA2865288A1/en not_active Abandoned
- 2013-02-22 HK HK15102126.6A patent/HK1201541A1/xx unknown
- 2013-02-22 NZ NZ629309A patent/NZ629309A/en unknown
- 2013-02-22 JP JP2014558206A patent/JP2015509714A/ja active Pending
- 2013-02-22 EP EP13706693.2A patent/EP2817326A1/en not_active Withdrawn
- 2013-02-22 WO PCT/GB2013/050433 patent/WO2013124666A1/en not_active Ceased
-
2017
- 2017-07-14 US US15/650,209 patent/US20180153987A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509714A5 (enExample) | ||
| CA3059199C (en) | Antibody fc variants for increased blood half-life | |
| JP2020531002A5 (enExample) | ||
| US20180215805A1 (en) | Therapeutic and diagnostic agents | |
| AU2013211824A1 (en) | Fusion proteins comprising IgG2 hinge domains | |
| AU2018382593B2 (en) | Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment | |
| AU2013223801B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2020517262A5 (enExample) | ||
| Xu et al. | A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A | |
| WO2022045276A1 (ja) | ヘテロ二量体Ｆｃポリペプチド | |
| TW202506723A (zh) | 結合fcrn之fc片段及使用方法 | |
| CN118369334A (zh) | 新型蛋白 | |
| TW202246331A (zh) | 人源化補體５ａ受體１抗體及其使用方法 | |
| CN117264054B (zh) | 靶向il-6的纳米抗体、组合物、方法及用途 | |
| US20190202908A1 (en) | Bi-specific agents | |
| WO2021007439A1 (en) | Bispecific antibodies to tnf-alpha and il-1beta and uses thereof | |
| CA3088131A1 (en) | Methods and compositions for treating hpa hyperactivity | |
| JP2019516360A (ja) | ヒト化抗ｒａｇｅ抗体 | |
| CN116897159A (zh) | 截短的taci多肽及其融合蛋白和用途 | |
| CN117377688A (zh) | 人源化补体5a受体1抗体和其使用方法 | |
| CN116970078A (zh) | 一种抗TrkA的抗体及其在宠物中的应用 | |
| EP4540274A1 (en) | Follistatin-fc fusion proteins | |
| JPWO2022165067A5 (enExample) |